Wall Street is positive on Nektar Therapeutics (NKTR). On average, analysts give Nektar Therapeutics a Buy rating. The average price target is $21.444, which means analysts expect the stock to increase by 47.79% over the next twelve months.
That average ranking earns Nektar Therapeutics an Analyst Rating of 28, which is better than 28% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating NKTR a Buy today. Find out what this means to you and get the rest of the rankings on NKTR!
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Nektar Therapeutics Stock Today?
Nektar Therapeutics (NKTR) stock is trading at $14.51 as of 11:40 AM on Wednesday, Dec 29, a loss of -$0.53, or -3.52% from the previous closing price of $15.04. The stock has traded between $14.42 and $14.91 so far today. Volume today is light. So far 559,985 shares have traded compared to average volume of 3,047,752 shares.
Click Here to get the full Stock Report for Nektar Therapeutics stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
